Fladrafinil (CRL-40,941)

Fladrafinil Article

Fladrafinil (CRL-40,941)

Fladrafinil, designated in pharmacological literature as CRL-40,941, is a synthetic fluorinated eugeroic compound structurally related to modafinil and adrafinil. It represents a modified bis(4-fluorophenyl)methylsulfinyl derivative featuring a terminal hydroxamic acid moiety. Within neurobiology and behavioral pharmacology research, fladrafinil is investigated as a high-precision reference standard for evaluating the central mechanisms of wakefulness, sustained vigilance, and psychostimulant kinetics. The strategic inclusion of twin para-fluorine atoms on its aromatic rings modifies the compound’s electronic configuration, altering its resistance to metabolic oxidation while enhancing central nervous system penetration parameters compared to non-fluorinated parent structures.

Technical Specifications

Research Applications & Mechanism of Interest

The primary value of fladrafinil in advanced laboratory settings centers on its selective interaction with central monoaminergic transporter systems to elevate extracellular neurotransmitter levels without triggering the severe autonomic overstimulation common to classical amphetamine-class psychostimulants.

Primary fields of preclinical and in vitro laboratory study include:

• Dopamine Transporter (DAT) Binding Assays: Measuring competitive ligand binding affinities at the dopamine transporter site. Fladrafinil acts to partially block DAT, slowing the reuptake of endogenous dopamine and extending signaling periods within the synaptic cleft.

• Vigilance and Wakefulness Modeling: Evaluating behavioral shifts and EEG sleep-wake architectures in animal models. Researchers utilize the compound to study long-term focus, task endurance, and resistance to induced fatigue markers.

• Metabolic Resistance Profiles: Tracking the kinetic stability of di-fluorinated phenyl groups during exposure to hepatic microsomal enzymes. The strong carbon-fluorine bonds are studied for their role in delaying standard metabolic clearance loops.

• Orexinergic and Histaminergic Synergy: Investigating secondary downstream activations within the tuberomammillary nucleus and lateral hypothalamus to observe how DAT inhibition indirectly balances sleep-regulating peptide signals.

Storage & Handling Guidelines

To eliminate any risk of environmental breakdown, secure compound stability, and safeguard precise analytical test parameters:

• Thermal Settings: Store bulk powder consistently in a cool, dry location. Long-term master reference stocks are best maintained under deep freeze conditions (-20°C).

• Atmospheric Safeguards: Keep containment caps tightly and hermetically sealed to isolate the chemical matrix from ambient humidity, prevents localized moisture absorption, and protects the terminal hydroxamic acid chain.

• Photolytic Protections: Protect from direct light arrays and intensive laboratory ultraviolet (UV) radiation by utilizing original opaque containers or amber glass containment vessels.

• Analytical Quality Assays: Kimera Chems subjects every batch to a strict dual-method verification protocol combining High-Performance Liquid Chromatography (HPLC) and CHN elemental analysis to independently confirm absolute identity, structural purity parameters, and complete compound safety baselines before distribution.

Research Use Only Disclaimer: This product is developed, synthesized, and distributed strictly as a Research Use Only (RUO) laboratory reference chemical intended exclusively for non-clinical analytical and scientific investigation. It is not an FDA-approved drug formulation, active pharmaceutical ingredient, or dietary supplement, and is strictly prohibited for human or veterinary consumption. Kimera Chems supplies these high-purity compounds solely to accredited institutional laboratories and certified scientific investigators.